Testosterone Replacement Therapy in Men With Hypogonadism and HIV/AIDS: Results From the TRiUS Registry

References

• . Bhasin S, Storer TW. Anabolic applications of androgens for functional limitations associated with aging and chronic illness. Front Harm Res. 2009;37:163–182
   PubMed Web of Science ®Google Scholar
• . Chan DJ. Erectile dysfunction in men with HIV-1: effect of hypogonadism and antiretroviral therapy. J HIV Ther. 2007;12(2):54–58
   PubMedGoogle Scholar
• . Crum-Cianflone NF, Bavaro M, Hale B, . Erectile dysfunction and hypogonadism among men with HIV. AIDS Patient Care STDS. 2007;21(1):9–19
   PubMed Web of Science ®Google Scholar
• . Teichmann J, Lange U, Discher T, Lohmeyer J, Stracke H, Bretzel RG. Bone mineral density in human immunodeficiency virus-1 infected men with hypogonadism prior to highly-active-antiretroviral-therapy (HAART). Eur J Med Res. 2009;14(2):59–64
   PubMed Web of Science ®Google Scholar
• . Grinspoon S, Corcoran C, Stanley T, Baaj A, Basgoz N, Klibanski A. Effects of hypogonadism and testosterone administration on depression indices in HIV-infected men. J Clin Endocrinol Metab. 2000;85(1):60–65
   PubMed Web of Science ®Google Scholar
• . Zarrouf FA, Artz S, Griffith J, Sirbu C, Kommor M. Testosterone and depression: systematic review and meta-analysis. J Psychiatr Pract. 2009;15(4):289–305
   PubMed Web of Science ®Google Scholar
• . Rabkin JG, Rabkin R, Wagner GJ. Testosterone treatment of clinical hypogonadism in patients with HIV/AIDS. Int J STD AIDS. 1997;8(9):537–545
   PubMedGoogle Scholar
• . Rabkin JG, Wagner GJ, Rabkin R. Testosterone therapy for human immunodeficiency virus-positive men with and without hypogonadism. J Clin Psychopharmacol. 1999;19(1):19–27
   PubMedGoogle Scholar
• . Tindall B, Forde S, Goldstein D, Ross MW, Cooper DA. Sexual dysfunction in advanced HIV disease. AIDS Care. 1994;6(1):105–107
   PubMed Web of Science ®Google Scholar
• . Blute M, Hakimian P, Kashanian J, Shteynshluyger A, Lee M, Shabsigh R. Erectile dysfunction and testosterone deficiency. Front Harm Res. 2009;37:108–122
   PubMed Web of Science ®Google Scholar
• . Khera M, Bhattacharya RK, Blick G, Kushner H, Nguyen D, Miner MM. Improved sexual function with testosterone replacement therapy in hypogonadal men: real-world data from the Testim Registry in the US (TRiUS). J Sex Med. 2011;8(11):3204–3213
   PubMedGoogle Scholar
• . Bhasin S, Cunningham GR, Hayes FJ, . Testosterone therapy in adult men with androgen deficiency syndromes: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2006;91(6):1995–2010
   PubMed Web of Science ®Google Scholar
• . Bhasin S, Cunningham GR, Hayes FJ, . Testosterone therapy in men with androgen deficiency syndromes: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2010;95(6):2536–2559
   PubMed Web of Science ®Google Scholar
• . Mulligan T, Frick MF, Zuraw QC, Stemhagen A, McWhirter C. Prevalence of hypogonadism in males aged at least 45 years: the HIM study. Int J Clin Pract. 2006;60(7):762–769
   PubMed Web of Science ®Google Scholar
• . AACE Hypogonadism Task Force. American Association of Clinical Endocrinologists medical guidelines for clinical practice for the evaluation and treatment of hypogonadism in adult male patients—2002 update. Endocr Pract. 2002;8(6):439–456
   Google Scholar
• . Maggi M, Schulman C, Quinton R, Langham S, Uhl-Hochgraeber K. The burden of testosterone deficiency syndrome in adult men: economic and quality-of-life impact. J Sex Med. 2007;4(pt 1):1056–1069
   PubMed Web of Science ®Google Scholar
• . Araujo AB, Esche GR, Kupelian V, . Prevalence of symptomatic androgen deficiency in men. J Clin Endocrinol Metab. 2007;92(11):4241–4247
   PubMed Web of Science ®Google Scholar
• . Kelleher S, Conway AJ, Handelsman DJ. Blood testosterone threshold for androgen deficiency symptoms. J Clin Endocrinol Metab. 2004;89(8):3813–3817
   PubMedGoogle Scholar
• . Darby E, Anawalt BD. Male hypogonadism: an update on diagnosis and treatment. Treat Endocrinol. 2005;4(5):293–309
   PubMedGoogle Scholar
• . English KM, Steeds RP, Jones TH, Diver MJ, Channer KS. Low-dose transdermal testosterone therapy improves angina threshold in men with chronic stable angina: a randomized, double-blind, placebo-controlled study. Circulation. 2000;102(16):1906–1911
   PubMed Web of Science ®Google Scholar
• . Ensrud KE, Lewis CE, Lambert LC, . Endogenous sex steroids, weight change and rates of hip bone loss in older men: the MrOS study. Osteoporos Int. 2006;17(9):1329–1336
   PubMedGoogle Scholar
• . Kapoor D, Goodwin E, Channer KS, Jones TH. Testosterone replacement therapy improves insulin resistance, glycaemic control, visceral adiposity and hypercholesterolaemia in hypogonadal men with type 2 diabetes. Eur J Endocrinol. 2006;154(6):899–906
   PubMed Web of Science ®Google Scholar
• . LeBlanc ES, Nielson CM, Marshall LM, . The effects of serum testosterone, estradiol, and sex hormone binding globulin levels on fracture risk in older men. J Clin Endocrinol Metab. 2009;94(9):3337–3346
   PubMed Web of Science ®Google Scholar
• . Meier C, Nguyen TV, Handelsman DJ, . Endogenous sex hormones and incident fracture risk in older men: the Dubbo Osteoporosis Epidemiology Study. Arch Intern Med. 2008;168(1):47–54
   PubMedGoogle Scholar
• . Naharci MI, Pinar M, Bolu E, Olgun A. Effect of testosterone on insulin sensitivity in men with idiopathic hypogonadotropic hypogonadism. Endocr Pract. 2007;13(6):629–635
   PubMedGoogle Scholar
• . Svartberg J, Agledahl I, Figenschau Y, Sildnes T, Waterloo K, Jorde R. Testosterone treatment in elderly men with subnormal testosterone levels improves body composition and BMD in the hip. Int J Impot Res. 2008;20(4):378–387
   PubMed Web of Science ®Google Scholar
• . Steidle C, Schwartz S, Jacoby K, Sebree T, Smith T, Bachand R. AA2500 testosterone gel normalizes androgen levels in aging males with improvements in body composition and sexual function. J Clin Endocrinol Metab. 2003;88(6):2673–2681
   PubMed Web of Science ®Google Scholar
• . McNicholas TA, Dean JD, Mulder H, Carnegie C, Jones NA. A novel testosterone gel formulation normalizes androgen levels in hypogonadal men, with improvements in body composition and sexual function. BJU Int. 2003;91(1):69–74
   PubMedGoogle Scholar
• . Kaminetsky JC. Benefits of a new testosterone gel formulation for hypogonadal men. Clin Cornerstone. 2005;7( suppl 4):S8–S12
   PubMedGoogle Scholar
• . Clay PG, Voss LE, Williams C, Daume EC. Valid treatment options for osteoporosis and osteopenia in HIV-infected persons. Ann Pharmacother. 2008;42(5):670–679
   PubMedGoogle Scholar
• . Grinspoon S, Corcoran C, Lee K, . Loss of lean body and muscle mass correlates with androgen levels in hypogonadal men with acquired immunodeficiency syndrome and wasting. J Clin Endocrinol Metab. 1996;81(11):4051–4058
   PubMed Web of Science ®Google Scholar
• . Grinspoon S, Corcoran C, Askari H, . Effects of androgen administration in men with the AIDS wasting syndrome. A randomized, double-blind, placebo-controlled trial. Ann Intern Med. 1998;129(1):18–26
   PubMed Web of Science ®Google Scholar
• . Kong A, Edmonds P. Testosterone therapy in HIV wasting syndrome: systematic review and meta-analysis. Lancet Infect Dis. 2002;2(11):692–699
   PubMedGoogle Scholar
• . Schrader S, Mills A, Scheperle M, Block JE. Improvement in sexual functioning and satisfaction in nonresponders to testosterone gel: clinical effectiveness in hypogonadal, HIV-positive males. Clin Cornerstone. 2005;7( suppl 4): S26–S31
   Google Scholar
• . Miner MM, Khera M, Bhattacharya R, Blick G, Kushner H. Baseline data from the TRiUS registry: symptoms and comorbidities of testosterone deficiency. Postgrad Med. 2011;123(3):17–27
   PubMed Web of Science ®Google Scholar
• . Gliklich RE, Bertagna M. The emerging role of the patient registry. Good Clin Pract J. 2006;13(12):14–17
   Google Scholar
• . Khera M, Bhattacharya RK, Blick G, Kushner H, Nguyen D, Miner MM. Changes in prostate specific antigen in hypogonadal men after 12 months of testosterone replacement therapy: support for the prostate saturation theory. J Urol. 2011;186(3):1005–1011
   PubMed Web of Science ®Google Scholar
• . Bhattacharya RK, Khera M, Blick G, Kushner H, Nguyen D, Miner MM. Effect of 12 months of testosterone replacement therapy on metabolic syndrome components in hypogonadal men: data from the Testim Registry in the US (TRiUS). BMC Endocr Disord. 2011;11(1):18
   PubMedGoogle Scholar
• . Khera M, Bhattacharya RK, Blick G, Kushner H, Nguyen D, Martin MM. The effect of testosterone supplementation on depression symptoms in hypogonadal men from the Testim Registry in the US (TRiUS). Aging Male. 2012;15(1): 14–21
   PubMed Web of Science ®Google Scholar
• . Blick G, Khera M, Bhattacharya RK, Nguyen D, Kushner H, Miner MM. Testosterone replacement therapy outcomes among opioid users: the Testim Registry in the United States (TRiUS). Pain Med. 2012;13(5):688–698
   PubMedGoogle Scholar
• . Bhattacharya RK, Khera M, Blick G, Kushner H, Miner MM. Testosterone replacement therapy among elderly males: the Testim Registry in the US (TRiUS). Clin Interv Aging. 2012;7:321–330
   PubMed Web of Science ®Google Scholar
• . O'Leary MR Fowler FJ, Lenderking WR, . A brief male sexual function inventory for urology. Urology. 1995;46(5):697–706
   PubMed Web of Science ®Google Scholar
• . Kroenke K, Spitzer RL, Williams JB. The PHQ-9: validity of a brief depression severity measure. J Gen Intern Med. 2001;16(9):606–613
   PubMed Web of Science ®Google Scholar
• . Linton MF, Fazio S. A practical approach to risk assessment to prevent coronary artery disease and its complications. Am J Cardiol. 2003;92(1A):19i–26i
   Google Scholar
• . Vermeulen A. Declining androgens with age: an overview. In: Vermeulen A Oddens BJ, eds. Androgens and the Aging Male. New York, NY: Parthenon Publishing; 1996:3–14
   Google Scholar
• . Dean JD, Carnegie C, Rodzvilla J, Smith T. Long-term effects of Testim® 1% testosterone gel in hypogonadal men. Rev Urol. 2005;7(2):87–94
   PubMedGoogle Scholar
• . Grober ED, Khera M, Soni SD, Espinoza MG, Lipshultz LI. Efficacy of changing testosterone gel preparations (Androgel or Testim) among suboptimally responsive hypogonadal men. Int J Impot Res. 2008;20(2):213–217
   PubMedGoogle Scholar
• . Scott JD, Wolfe PR, Anderson P, Cohan GR, Scarsella A. Prospective study of topical testosterone gel (AndroGel) versus intramuscular testosterone in testosterone-deficient HIV-infected men. HIV Clin Trials. 2007;8(6):412–420
   PubMed Web of Science ®Google Scholar
• . Bhasin S, Calof OM, Storer TW, . Drug insight: testosterone and selective androgen receptor modulators as anabolic therapies for chronic illness and aging. Nat Clin Pract Endocrinol Metab. 2006;2(3):146–159
   PubMedGoogle Scholar
• . Lin D, Rieder MJ. Interventions for the treatment of decreased bone mineral density associated with HIV infection. Cochrane Database Syst Rev. 2007;2:CD005645
   Google Scholar
• . Allan CA, Strauss BJ, Burger HG, Forbes EA, McLachlan RI. Testosterone therapy prevents gain in visceral adipose tissue and loss of skeletal muscle in nonobese aging men. J Clin Endocrinol Metab. 2008;93(1):139–146
   PubMed Web of Science ®Google Scholar
• . Grinspoon S, Corcoran C, Parlman K, . Effects of testosterone and progressive resistance training in eugonadal men with AIDS wasting. A randomized, controlled trial. Ann Intern Med. 2000;133(5):348–355
   PubMed Web of Science ®Google Scholar
• . Roubenoff R. Acquired immunodeficiency syndrome wasting, functional performance, and quality of life. Am J Manag Care. 2000;6(9):1003–1016
   PubMed Web of Science ®Google Scholar
• . Tebas P, Powderly WG, Claxton S, . Accelerated bone mineral loss in HIV-infected patients receiving potent antiretroviral therapy. AIDS. 2000;14(4):F63–F67
   PubMed Web of Science ®Google Scholar
• . Brown TT, Qaqish RB. Antiretroviral therapy and the prevalence of osteopenia and osteoporosis: a meta-analytic review. AIDS. 2006;20(17):2165–2174
   PubMed Web of Science ®Google Scholar
• . Calmy A, Hirschel B, Cooper DA, Carr A. A new era of antiretroviral drug toxicity. Antivir Ther. 2009;14(2):165–179
   PubMed Web of Science ®Google Scholar
• . Grijsen ML, Vrouenraets SM, Steingrover R, . High prevalence of reduced bone mineral density in primary HIV-1-infected men. AIDS. 2010;24(14):2233–2238
   PubMed Web of Science ®Google Scholar
• . Arnsten JH, Freeman R, Howard AA, Floris-Moore M, Lo Y, Klein RS. Decreased bone mineral density and increased fracture risk in aging men with or at risk for HIV infection. AIDS. 2007;21(5):617–623
   PubMed Web of Science ®Google Scholar
• . McArthur JC, Brew BJ. HIV-associated neurocognitive disorders: is there a hidden epidemic? AIDS. 2010;24(9):1367–1370
   PubMed Web of Science ®Google Scholar
• . Simioni S, Cavassini M, Annoni JM, . Cognitive dysfunction in HIV patients despite long-standing suppression of viremia. AIDS. 2010;24(9):1243–1250
   PubMed Web of Science ®Google Scholar